.

.

Ironwood (Nasdaq: IRWD) is spending the. 1 day ago · As of May 11, 2023, the average one-year price target for Ironwood Pharmaceuticals Inc - is 13.

(NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K.

.

IRWD reported first-quarter 2023 adjusted earnings of 25 cents per share, which beat both the Zacks Consensus Estimate and our model estimates of 24 cents and 23. . 63%).

.

ironwoodpharma. . .

. .

.

63%).

May 22, 2023. The average price target represents.

. .

May 5, 2023 · From 2008 until May 2015, Mr.
.
Consylman served as Interim Chief Financial Officer and Vice President of.

m.

63%).

Ironwood Announces Departure of CFO, Names Permanent CEO. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. .

(“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that they have entered into a definitive. . Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. . . It certainly bolsters Ironwood as a GI.

CAMBRIDGE, Mass.

Listen to this article 3 min. .

This week, Ironwood Pharmaceuticals announced a big acquisition.

Ironwood Announces Departure of CFO, Names Permanent CEO.

.

2 days ago · Ironwood Pharmaceuticals Inc said on Monday it would buy Switzerland-based drug developer VectivBio Holding AG for $1.

.